Position of the Transparency Council – Fabhalta (iptacopan)

At its meeting on 14 April 2025, the Transparency Council adopted position No. 41/2025 on the evaluation of a medicinal product Fabhalta (iptacopan) under drug program B.96 “Treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 D59.5)”

Publication of the position >>